Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI LODR''), we wish to inform ....

F l 0 & HOLOGtc® ADS DIAGNOSTIC LIMITED THE SCIENCE OF SURE ADS/BSE/2026-27 /08/06 13th August, 2026 The General Manager Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai, Maharashtra - 400 001 Sub- Outcome of the Board Meeting for the quarter ended June 30, 2023 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Company Code - 523031 Dear Sir, Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors (the 'Board') of ADS Diagnostic Limited ('the Company') at its meeting held today i.e. Thursday, August 13th, 2026 considered and approved the Unaudited Standalone-Financial Results of the Company for the quarter ended 30th June, 2026. The Board Meeting commenced at 12:05 p.m. and concluded at 13:10 p.m Thanking You Yours Faithfully N.L. Gayari CFO & Company Secretary ADS DIAGNOSTIC LIMITED . 114, SANT NAGAR, EAST OF !K9AIL.A SH, NEW DELHI -1.1 0065 TEL.. 011-41622193, 41620434, FAX.: 011-41665880 CIN-: L85110DL 1984PLC018486 Ud . ' .. 07290037529, E-mail: adsmedical@rediffmail.com , yam Reg1strat1on Number (MSME)- UDYAM-DL-08-0007361 F I W S HOLOGtC® ADS DIAGNOSTIC LIMITED THE SCIENCE OF SURE STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30.06.2026 (Rs. In Lakhs) Quarter Ended Year Ended PARTICULARS 30.06.2026 30.06.2025 31.03.2026 31.03.2026 Unaudited Unaudited Audited Audited 1 Income from Ooerations a) Revenue from Ooerations (Net) 328.21 426.68 400.30 2 835.75 b) Other Ooeratina Income 23.33 13.36 3.68 13.26 Total Income {a+b) 351.54 440.04 403.98 2,849.01 2 Exoenses a) Cost of materials Consumed 47.19 222.18 191.45 1 657.58 b) Emolovee benefits exoense 74.38 68.38 84.52 321.70 c) Deoreciation and amortisation exoense 1.29 2.84 (1.751 5.75 d) Finance costs 10.27 11.91 13.45 61.12 e) Other expenses 214.38 114.69 99.23 658.29 Total exoenses Ca+b+c+d+e) 347.51 420.00 386.90 2.704.44 3 Profit / Closs) before Tax and Exceptional Items (1-2) 4.03 20.04 17.08 144.57 a) Execeotional Item - - - - 4 Profit/ Closs) before Tax 4.03 20.04 17.08 144.57 5 Tax exoenses a) Current Income Tax 0.81 5.27 3.74 35.83 b) Income Tax -Earlier Years - - - - c) Deferred tax charae - - 1.70 1.70 Total Tax Exoenses (a+b+c) 0.81 5.27 5.45 37.54 6 Net Profit & Loss after Tax for the period ( 4-5) 3.22 14.77 11.64 107.04 7 Other Comorehensive Income, Net on Income Tax a) n Items that will not be reclassified to orofit or loss - - (0.981 (0.98) ii) Income tax relatina to items that will not be reclassified to profit or loss - - 1.20 1.20 b) i) Items that will be reclassified to orofit or loss - - - - ii) Income tax relatino to items that will be reclassified to profit or loss - - - - Total other comorehensive income. net of income tax 0.22 0.22 8 Total comorehensive income after tax (6+7) 3.22 14.77 11.86 107.26 9 Paid-uo Eauitv Share caoital <Face Value of Rs 10/-each) 219.28 219.28 219.28 219.28 10 Reserve excluding Revaluation Reserves as per Balance Sheet of Previous 519.76 434.43 434.43 434.43 Accounting Year 11 Earninas Per Share <EPS) (Rs.) (not annualised) a) Basic EPS 0.15 0.67 0.53 4.88 b) Diluted EPS 0.15 0.67 0.53 4.88 Notes t) The above Unaudited Financial Results were reviewed by the Audit Committee and approved by Board of Directors at their respective meetings held on 13th August, 2026 2) The Company is engaged in the business of "Trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines" and, therefore, has only one reportable segment In accordance with Ind AS 108 "Operating Segments". 3) Figures for the previous period have been recast/ regrouped/ rearranged, wherever necessary, to conform to the current period's classification. 4) The above results have been prepared In compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and relevant amendment rules thereafter. 5) These Results are also updated on the company's website URL: http://www.adsdiagnostlcltd.com Place : New Delhi Dr. Gautam Sehgal Date : 13th August 2026 Managing Director DIN 00034243 114, SANT NAGAR, EAST OF KAILASH, NEW DELHI -110065 TEL.: 011-41622193, 41620434, FAX.: 011-41665880, 07290037529, E-mail: adsmedical@rediffmail.com CIN-: L85110DL 1984PLC018486, Udyam Registration Number (MSME)- UDYAM-DL-08-0007361 214, New Delhi House, (fl{ 27, Barakhamba Road, V.N. PUROHIT B: CO. New Delhi - 110001 1N o,} Ph: +91 11 43596011; CHARTERED ACCOUNTANTS Email: delhi@vnp.in; Web: http://www.vnp.in INDEPENDENT AUDITOR'S REVIEW REPORT ON THE g_UARTERL Y UNAUDITED FINANCIAL RESULTS To Board of Directors of A D S Diagnostic Limited 114, Sant Nagar, East of Kailash, New Delhi - 110065 (CIN: L85110DL1984PLC018486) We have reviewed the accompanying stat~ment of unaudited financial results (the "Statement") of Mis. A D S Diagnostic Limited (the "Company") for the quarter ended on 30th June, 2026, being submitted by the Company pursuant to requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This statement which is the responsibility of the Company's Management has been approved by the Board of Directors has been prepared according to the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. FOR V. N. PUROHIT & CO. Chartered Accountants Firm Regn. 304040E ,-Digitally signed by Om Prakas~.om Prakash Pareek Pareek / _Date:2026.08.13 // 12:40:09 +05'30' 0. P. Pareek Partner Membership No. 014238 UDIN: 26014238NMXXUV8539 New Delhi, the 13th day of August, 2026 I I I l<OLKATA DELHI HYDERABAD DURGAPUR